TRex Bio
TRex Bio is a biotechnology company that develops treatments for immune-mediated diseases using a human tissue-based platform combined with machine learning and high-throughput '-omics'.
Company Overview
TRex Bio utilizes a human tissue-based Deep Biology Platform for drug discovery and development targeting immune-mediated diseases. The company's unique approach focuses on modifying diseases at the tissue level to restore tissue homeostasis using a Treg-focused approach. The combination of human tissue biology with machine learning and high-throughput '-omics' positions TRex Bio at the forefront of innovative drug discovery.
Key Collaborations
TRex Bio has established significant collaborations to enhance its research and development capabilities. The company collaborates with Janssen to discover novel targets for immunology and inflammation. Additionally, collaborations with Eli Lilly and Janssen Pharmaceutica NV focus on identifying new targets for treating inflammatory and autoimmune diseases. These partnerships aim to leverage TRex Bio's platform for groundbreaking discoveries in immunology.
Development Pipeline
TRex Bio's pipeline includes multiple large molecule therapeutic candidates aimed at inflammatory and autoimmune diseases, as well as fibrosis. Key among these candidates is TRB-061, a novel TNFR2 agonist designed for treating inflammatory diseases. This candidate signifies the company's advance in developing therapies targeting specific mechanisms within the immune system.
Funding and Investment
TRex Bio has secured significant funding to propel its innovative research. The company completed a $26 million Series A extension led by Polaris Partners to further its treatments for immune-mediated diseases. This followed an earlier $59 million Series A financing aimed at advancing innovation in tissue immunobiology for cancer and inflammatory diseases treatment. These funds underscore investor confidence in TRex Bio's approach and potential impact.